CHAIR
:
SPEAKER
(S):
Thomas Gunning, Vice President and General Counsel, EMD Serono, Inc.
David Reid, Senior Vice President and Associate General Counsel, Pfizer, Inc.
Carol Greve-Philips, Senior Director of Business Development, Corporate Group, Genzyme Corporation
Description
The past few years have seen a significant increase in merger and acquisition activity in the biotechnology industry. This session focuses on the business objectives and strategies behind the decision to embark on an acquisition, from the perspective of both the acquirer and the acquired.
Objectives:
Learn the relative advantages of pursuing acquisition, partnering, IPO, private equity or other transaction.
Learn what to look for in a potential target/buyer.
Learn how to structure the deal and what to expect after the acquisition.